Fundz

BioCryst Pharmaceuticals

Durham, North Carolina, United States · Biotechnology, Health Care, Therapeutics

BioCryst is focused on developing novel therapies for diseases with significant unmet needs. The company has already commercialized ORLADEYO® (berotralstat), a once-daily oral plasma kallikrein inhibitor, and continues to develop a pipeline of small-molecule and protein therapies.

Key facts

Headquarters
Durham, North Carolina, United States
Employees
440
Industries
Biotechnology, Health Care, Therapeutics
Status
Public (BCRX)
Website
http://www.biocryst.com/
LinkedIn
Company page

Recent activity at BioCryst Pharmaceuticals

  • : BioCryst acquires Astria Therapeutics for drug access
  • : BioCryst Pharmaceuticals Appoints David W. Jenkins as Chief Scientific Officer
  • : BioCryst Pharmaceuticals pivots to cost-saving partnerships and ends internal discovery programs. (date Fundz recorded it)
  • : SEC 8-K (7.01):
  • : SEC 8-K (7.01):
  • : SEC 8-K (2.05):
  • : SEC 8-K (5.02): On June 11, 2026, at the 2026 Annual Meeting of Stockholders of BioCryst Pharmaceuticals, Inc., stockholders voted to amend and restate the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan, increasing the number of shares available for issuance under the plan by 7,000,000 shares. This proposal, known as the Incentive Plan Proposal, was approved by a majority vote of the shares represented at the meeting. The Annual Meeting also included the election of three directors for a term ending in 2029 and the ratification of Ernst & Young LLP as the Company’s independent auditors for 2026. Key voting results included significant majorities in favor of the directors and auditors, while the compensation resolution saw notable opposition with over 56 million votes against it.
  • : SEC 8-K (5.02): On June 11, 2026, BioCryst Pharmaceuticals, Inc. held its Annual Meeting of Stockholders where stockholders approved an amendment to the Stock Incentive Plan. This amendment allows for an increase of 7,000,000 shares available for issuance under the plan. The approval was received by a majority vote from the shares of common stock represented at the meeting. This change is significantly aimed at enhancing employee compensation and retention strategies through increased stock options, thus potentially influencing the company's long-term performance and employee morale.
  • : SEC 8-K (7.01):
  • : SEC 8-K (7.01): On May 4, 2026, BioCryst Pharmaceuticals, Inc. announced a Regulation FD disclosure regarding a licensing agreement with an Irish affiliate of Neopharmed Gentili S.p.A. This agreement grants exclusive rights to commercialize navenibart for hereditary angioedema in Europe. The Company will receive an upfront payment of $70 million and may earn up to $275 million in future regulatory and sales milestone payments, along with tiered royalties on net sales ranging from 18% to 30%. This deal highlights BioCryst's strategic focus on expanding the commercialization of navenibart in the European market.

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

BioCryst Pharmaceuticals funding history

DateRoundAmount
Nov 2021Funding Round$350.0M

Leadership

  • David W. Jenkins, Chief Scientific Officer
  • Warren English, Chief Technology Officer
  • Anthony Doyle, Chief Financial Officer
  • Jon Stonehouse, Chief Executive Officer
  • Bob Stoner, Vice President Human Resources
  • Suzie Paulson
  • Lance Walton, Senior Finance Professional
  • Mike Jones, Executive Director, Finance
  • Vijay Darekar, Senior Leader
  • Alex Y., End User Device Engineer

Verified email and direct lines for BioCryst Pharmaceuticals’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.

Employee benefit plans

BioCryst Pharmaceuticals files 3 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

Companies similar to BioCryst Pharmaceuticals

About BioCryst Pharmaceuticals: questions and answers

What does BioCryst Pharmaceuticals do?

BioCryst is focused on developing novel therapies for diseases with significant unmet needs. The company has already commercialized ORLADEYO® (berotralstat), a once-daily oral plasma kallikrein inhibitor, and continues to develop a pipeline of small-molecule and protein therapies.

Where is BioCryst Pharmaceuticals headquartered?

BioCryst Pharmaceuticals is headquartered in Durham, North Carolina, United States.

How many employees does BioCryst Pharmaceuticals have?

BioCryst Pharmaceuticals has about 440 employees.

Has BioCryst Pharmaceuticals raised funding?

Yes. Fundz has recorded 1 funding event for BioCryst Pharmaceuticals. The most recent, Funding Round of $350.0M, was in Nov 2021.

Who leads BioCryst Pharmaceuticals?

Jon Stonehouse is a Chief Executive Officer at BioCryst Pharmaceuticals.

What is the latest news on BioCryst Pharmaceuticals?

On Aug 29, 2026, BioCryst acquires Astria Therapeutics for drug access

Is BioCryst Pharmaceuticals a public company?

Yes. BioCryst Pharmaceuticals is publicly traded under the ticker BCRX.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches BioCryst Pharmaceuticals across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.